MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Anticholinergic Use in Parkinson’s Disease: Practice Patterns in Patients with Cognitive Impairment

N. Shetty, O. Dubaz, Y. Yu, H. Gao, T. Simuni (Chicago, IL, USA)

Meeting: MDS Virtual Congress 2020

Abstract Number: 437

Keywords: Anticholinergic medications, Cognitive dysfunction

Category: Parkinson's Disease: Cognitive functions

Objective: To explore utilization of anticholinergic medications using the Parkinson Foundation Quality Improvement Initiative (PF-QII) registry.

Background: Recent publications have highlighted the association between anticholinergic medication use and increased rates of dementia diagnoses. However, despite accumulating data on the negative cognitive impact of anticholinergics, these medications remain part of the treatment armamentarium in Parkinson’s disease (PD).

Method: Data were collected from the PF-QII registry, an international multi-center prospective study of PD care and outcomes at expert centers. Frequency of anticholinergic use in the cohort was analyzed, and characteristics of anticholinergic users and non-users were compared. Utilization rates of anticholinergics in patients with and without cognitive dysfunction were compared. Additionally, frequency of hospitalizations and ER visits (HER) was compared between anticholinergic users and non-users.

Results: 201 (3.4%) out of 5,949 patients were on anticholinergics at baseline visit. Compared to non-users, anticholinergic users tended to be younger (64.5±9.0 vs, 68.2±9.1, p<0.0001) and perform worse on immediate 5 word recall (4.2±1.0 vs 4.4±0.9, p=0.013). Among patients with and without cognitive dysfunction, 2.72% and 3.53% (p=0.21) were anticholinergic users, respectively. Among anticholinergic users and non-users, 38.3% and 43.4% (p=0.73) had HER, respectively.

Conclusion: Although there has been a decline in overall utilization of anticholinergics in the PD population, there remains persistent use of anticholinergics in patients with cognitive dysfunction. We additionally found that anticholinergic users performed worse on a cognitive task despite being younger than non-users. This highlights the need for greater education to improve clinicians’ prescribing practices for anticholinergics, given their potential for negative impact on cognition.

Poster presented at: American Academy of Neurology Annual Meeting; April 25, 2020; Toronto, ON, Canada.

To cite this abstract in AMA style:

N. Shetty, O. Dubaz, Y. Yu, H. Gao, T. Simuni. Anticholinergic Use in Parkinson’s Disease: Practice Patterns in Patients with Cognitive Impairment [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/anticholinergic-use-in-parkinsons-disease-practice-patterns-in-patients-with-cognitive-impairment/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/anticholinergic-use-in-parkinsons-disease-practice-patterns-in-patients-with-cognitive-impairment/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley